Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
16562
post-template-default,single,single-post,postid-16562,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Home > Blogs  > Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

02 May Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Posted at 06:41h in Blogs by

In a phase 3 RUBY trial, dostarlimab combined with chemotherapy (carboplatin and paclitaxel) significantly increased progression-free survival as compared to placebo, with a substantial benefit in the dMMR–MSI-H population in patients with primary advanced stage III or IV or first recurrent endometrial Cancer. More severe and serious adverse events occurred in the dostarlimab group than in the placebo group. The safety profile of the combination was generally consistent with the known profiles of the individual drugs in the regimen. (Ref: Mirza MR, et al. N Engl J Med. March 27, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

No Comments

Sorry, the comment form is closed at this time.